

# Downstream Product-Based Payments Overcome an R&D Budget Gap

## Situation

A global pharmaceutical company had a promising new formulation of a marketed product in early Phase III trials, but R&D budget pressures were likely to result in delays getting the product to market.

## Solution

NovaQuest is funding \$200 million in development expenses related to the Phase III candidate. In return, it will receive a variety of product-based returns.

## Value Added

The deal resolves development budgetary gaps and is at a magnitude sufficient to jump start the product's development.

## New Heights. Together.

Contact Us:

*In the US:* 1 866 469 5395

*In Europe:* +44 (0) 1344 708070

*In other areas:* +1 919 998 1600

*Email:* [info@novaquest.com](mailto:info@novaquest.com)

> [novaquest.com](http://novaquest.com)



The Managed Partnership Group  
of Quintiles Transnational